ALECTINIB HYDROCHLORIDE

N/A

Manufactured by Genentech, Inc.

9,588 FDA adverse event reports analyzed

Last updated: 2026-04-15

About ALECTINIB HYDROCHLORIDE

ALECTINIB HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for ALECTINIB HYDROCHLORIDE include DEATH, FATIGUE, NO ADVERSE EVENT, OFF LABEL USE, CONSTIPATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALECTINIB HYDROCHLORIDE.

Top Adverse Reactions

DEATH673 reports
FATIGUE499 reports
NO ADVERSE EVENT461 reports
OFF LABEL USE451 reports
CONSTIPATION430 reports
RASH252 reports
DYSPNOEA227 reports
MYALGIA203 reports
WEIGHT INCREASED198 reports
DISEASE PROGRESSION197 reports
ASTHENIA183 reports
PERIPHERAL SWELLING175 reports
DRUG INEFFECTIVE167 reports
PAIN157 reports
NAUSEA156 reports
DIARRHOEA142 reports
PNEUMONIA136 reports
COUGH122 reports
OEDEMA120 reports
DIZZINESS115 reports
OEDEMA PERIPHERAL114 reports
ANAEMIA112 reports
HEADACHE112 reports
ARTHRALGIA105 reports
COVID 19104 reports
BLOOD BILIRUBIN INCREASED98 reports
PYREXIA96 reports
BRADYCARDIA85 reports
PLEURAL EFFUSION83 reports
HEPATIC FUNCTION ABNORMAL82 reports
PRURITUS81 reports
BLOOD CREATINE PHOSPHOKINASE INCREASED79 reports
METASTASES TO CENTRAL NERVOUS SYSTEM79 reports
DECREASED APPETITE75 reports
BACK PAIN74 reports
INTENTIONAL PRODUCT USE ISSUE74 reports
INTERSTITIAL LUNG DISEASE74 reports
MEMORY IMPAIRMENT74 reports
MALAISE73 reports
VOMITING73 reports
SWELLING72 reports
DYSPHAGIA71 reports
JOINT SWELLING70 reports
PAIN IN EXTREMITY68 reports
PHOTOSENSITIVITY REACTION68 reports
FALL67 reports
PNEUMONITIS67 reports
NEOPLASM MALIGNANT66 reports
PULMONARY OEDEMA66 reports
BLOOD CREATININE INCREASED65 reports
PRODUCT STORAGE ERROR64 reports
MUSCULAR WEAKNESS61 reports
NEUROPATHY PERIPHERAL60 reports
ALOPECIA59 reports
HAEMOGLOBIN DECREASED56 reports
FLUID RETENTION55 reports
HEART RATE DECREASED53 reports
INSOMNIA51 reports
MUSCLE SPASMS51 reports
HEPATIC ENZYME INCREASED50 reports
LUNG NEOPLASM MALIGNANT50 reports
HYPOAESTHESIA48 reports
NEOPLASM PROGRESSION48 reports
RENAL IMPAIRMENT48 reports
HYPOTENSION47 reports
LIVER DISORDER45 reports
THROMBOSIS45 reports
PERICARDIAL EFFUSION43 reports
SEIZURE43 reports
WEIGHT DECREASED43 reports
LIVER FUNCTION TEST INCREASED42 reports
URINARY TRACT INFECTION42 reports
CEREBROVASCULAR ACCIDENT41 reports
ABDOMINAL DISTENSION40 reports
HAEMOLYTIC ANAEMIA40 reports
TASTE DISORDER40 reports
ILL DEFINED DISORDER39 reports
NASOPHARYNGITIS39 reports
RENAL FAILURE38 reports
ABDOMINAL PAIN UPPER37 reports
CHEST PAIN37 reports
DYSGEUSIA37 reports
LUNG DISORDER37 reports
PRODUCT DOSE OMISSION ISSUE37 reports
ASPARTATE AMINOTRANSFERASE INCREASED36 reports
VISION BLURRED36 reports
SOMNOLENCE35 reports
ANXIETY34 reports
MALIGNANT NEOPLASM PROGRESSION34 reports
PARAESTHESIA34 reports
BRAIN NEOPLASM33 reports
GAIT DISTURBANCE33 reports
HOSPITALISATION33 reports
RED BLOOD CELL COUNT DECREASED33 reports
HYPERBILIRUBINAEMIA32 reports
HYPERSENSITIVITY32 reports
THERAPY INTERRUPTED32 reports
VISUAL IMPAIRMENT32 reports
BLOOD GLUCOSE INCREASED31 reports
CARDIAC FAILURE31 reports

Report Outcomes

Out of 6,963 classified reports for ALECTINIB HYDROCHLORIDE:

Serious 54.1%Non-Serious 45.9%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female3,852 (60.3%)
Male2,539 (39.7%)

Reports by Age

Age 72118 reports
Age 65114 reports
Age 70113 reports
Age 62110 reports
Age 74103 reports
Age 61101 reports
Age 68101 reports
Age 6798 reports
Age 6994 reports
Age 7193 reports
Age 6092 reports
Age 5690 reports
Age 6690 reports
Age 6389 reports
Age 7589 reports
Age 7386 reports
Age 7785 reports
Age 5984 reports
Age 7684 reports
Age 6482 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ALECTINIB HYDROCHLORIDE?

This profile reflects 9,588 FDA FAERS reports that mention ALECTINIB HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ALECTINIB HYDROCHLORIDE?

Frequently reported terms in FAERS include DEATH, FATIGUE, NO ADVERSE EVENT, OFF LABEL USE, CONSTIPATION, RASH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ALECTINIB HYDROCHLORIDE?

Labeling and FAERS entries often list Genentech, Inc. in connection with ALECTINIB HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.